Navigation Links
Collagenase for Dupuytren's contracture: Added benefit not proven
Date:7/12/2012

Collagenase extracted from Clostridium histolyticum (trade name: Xiapex) was approved in the beginning of 2011 for the treatment of people with Dupuytren's contracture. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether collagenase offers an added benefit in comparison with conventional regimens. However, such an added benefit cannot be inferred from the dossier, as the drug manufacturer presented either no data or unsuitable data.

Collagenase is to break down thickened connective tissue fibres

Dupuytren's contracture is a disorder of the hand in which connective tissue fibres in the palmar side of the hand (fasciae) thicken and harden. As a result, one or several fingers become permanently bent and can no longer be straightened. Collagenase is injected into the lesions to break down the thickened connective tissue fibres. One day later, the rupture of these fibres through passive digital extension is attempted in order to restore the stretching ability of the affected finger.

G-BA specifies different comparator therapies depending on disease stage

When specifying the appropriate comparator therapy, the Federal Joint Committee (G-BA) assumed that the choice of (conventional) treatment depends on how severely the function of the fingers and hand is impaired.

Hence, the G-BA stipulates four treatment alternatives and assigns them to different disease stages. The appropriate comparator therapies are specified as follows:

  • no treatment" in stage N, where no contracture yet exists;
  • percutaneous needle fasciotomy" (PNF), a minimally invasive technique, in stages N/I, I and II;
  • partial fasciectomy" (PF), open surgery of the hand, in stages III and IV.

If PF is not suitable for advanced-stage patients, a PNF can be performed.

No assessment performed for three of four possible comparisons

However, the manufacturer deviated from the G-BA's specifications and chose PF as a comparator therapy for the whole indication. IQWiG regards this deviation to be insufficiently justified.

Regarding the G-BA's first, second and fourth research questions (patients with stage N, stages N/I, I and II, as well as patients with advanced stages for whom PF is not an option), the manufacturer neither performed any assessment nor indicated studies for such comparisons in the study list.

An added benefit for these three sub-indications is thus not proven.

Requirements for an indirect comparison not fulfilled

For the third research question (patients with stage III or IV without contraindications for PF), the manufacturer met the G-BA's specifications in the submitted dossier, choosing PF as the comparator therapy. However, there is no study available that directly compares PF and collagenase. As an alternative, the manufacturer presented data from an indirect comparison.

The legal ordinance on AMNOG explicitly allows for the option that added benefit may also be proven by means of such indirect comparisons. However, certain preconditions apply here, which the manufacturer did not fulfil. Due to a lack of suitable data, an added benefit is therefore not proven for this research question either.

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Abiraterone: Indication of considerable added benefit in certain patients
2. Nurse Alert Provides Added Level of Senior Alert Care With New Nurse Triage Feature
3. Tafamidis: Approval denotes proven added benefit
4. No Added Cancer Risk From Hip Replacement Materials: Study
5. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia
6. Green Tea Weight Loss Results and Health Benefits Revealed
7. Early Surgery May Benefit Some With Heart Infection
8. How much would our health benefit from leaving the car at home?
9. MTSS-mba Membership Benefits Administration Software for Private and Taft-Hartley Employee Benefit Funds Releases New Pension Modules
10. Some Diabetics May Not Benefit From Daily Aspirin
11. Tai Chi increases brain size, benefits cognition in randomized controlled trial of Chinese elderly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National ... encouraging people all over the United States to thank a nurse who's made a ... will donate $5 to the American Red Cross of San Diego/Imperial Counties (up to ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group ... today announced a new collaboration with Imerman Angels to expand outreach and ... the world. , “Imerman Angels provides an emotional lifeline to patients and families facing ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Liposuction specialist Marcia ... Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s ... chosen to address the conference about her unique specialization in treating Lipedema. Dr. Byrd ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign ... their personal story and encourage those at risk to get tested and begin the road ... ... ... Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/3/2016)... 2016 Global and Chinese ... basic overview of the industry that covers definition, ... mesh report explores into the international and Chinese ... on Surgical Mesh market spread across 150 pages ... figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html . ...
Breaking Medicine Technology: